Autolus Therapeutics (NASDAQ:AUTL) Stock Price Down 5.1% - Here's Why

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report)'s stock price traded down 5.1% on Tuesday . The company traded as low as $2.55 and last traded at $2.52. 266,099 shares were traded during trading, a decline of 83% from the average session volume of 1,563,189 shares. The stock had previously closed at $2.65.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. Needham & Company LLC restated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, June 12th. Truist Financial reduced their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Wells Fargo & Company reduced their target price on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating for the company in a report on Friday, March 21st. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Performance

The business's 50 day moving average is $1.99 and its 200 day moving average is $1.89. The stock has a market cap of $642.73 million, a price-to-earnings ratio of -2.75 and a beta of 1.81.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $8.98 million for the quarter, compared to analysts' expectations of $1.59 million. Research analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Forefront Wealth Management Inc. purchased a new stake in Autolus Therapeutics in the 2nd quarter worth approximately $61,000. Avanza Fonder AB lifted its position in Autolus Therapeutics by 151.6% in the 2nd quarter. Avanza Fonder AB now owns 53,522 shares of the company's stock worth $122,000 after buying an additional 32,246 shares in the last quarter. Atle Fund Management AB lifted its position in Autolus Therapeutics by 130.5% in the 2nd quarter. Atle Fund Management AB now owns 1,105,461 shares of the company's stock worth $2,520,000 after buying an additional 625,817 shares in the last quarter. Jane Street Group LLC lifted its position in Autolus Therapeutics by 809.4% in the 1st quarter. Jane Street Group LLC now owns 102,493 shares of the company's stock worth $159,000 after buying an additional 91,222 shares in the last quarter. Finally, Armistice Capital LLC lifted its position in Autolus Therapeutics by 19.6% in the 1st quarter. Armistice Capital LLC now owns 11,000,000 shares of the company's stock worth $17,050,000 after buying an additional 1,800,000 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.